Day: February 16, 2024

Uponor Corporation, Stock Exchange Release, 16 February 2024 at 09:00 a.m. EET Uponor Corporation’s Financial Statements Bulletin 1–12/2023: Comparable operating profit margin increase amid turbulent markets October–December 2023 in brief Net sales were €277.6 (276.5) million, an increase of 0.4%. Organic growth adjusted for currencies was 7.9%. Comparable operating profit was €27.6 (11.0) million or 9.9% (4.0) of net sales. Operating profit was €0.8 (1.4) million or 0.3% (0.5) of net sales. Operating profit was impacted by extraordinary items affecting comparability of €26.8 million mainly in the month of October. These extraordinary items were related to one-time expenses related to the public tender offer. Earnings per share were €-0.09 (0.02). Important Note: The financial results for November–December will be fully consolidated into...

 QPR SOFTWARE PLC             STOCK EXCHANGE RELEASE          16 February 2024, AT 9.00 AM EETQPR Software Plc’s Financial Statement Bulletin 2023: SaaS net sales grew by 36%, and software business by 8%. Net sales decreased by 3% due to the discontinuation of consulting outside the core business in Finland. The strategy was adjusted. A significant improvement in EBITDA and cash flow turned positive.FINANCIAL DEVELOPMENT BRIEFLYOCTOBER-DECEMBER 2023SaaS net sales increased by +21% (53%) Net sales was 1,599 thousand euros, down -25% (October-December 2022: 2,142) due to company’s discontinuation of consulting outside the core business EBITDA was -30 thousand euros (-430), a change from the comparison period of 400 thousand The operating profit was -283 thousand euros (-681), a change from the comparison period of 398...

Large fluctuations in demand and a clear decline in the European heat pump market in the second half of the year. Action program to be initiated. Target of SEK 80 billion remains unchanged.   Sales rose by 16.4% to SEK 46,649 (40,071) million  Profit after net financial items amounted to SEK 6,331 (5,675) million Profit after net financial items in the previous year was boosted by non-recurring gains of SEK 118 million: SEK -114 million in Q1 and SEK +232 million in Q2  Earnings per share amounted to SEK 2.37 (2.16)  Dividend of SEK 0.65/share (SEK 0.65/share) proposed  Acquisitions of Miles Industries of Canada, Climate for Life of the Netherlands, Solzaima of Portugal, Ceramicx of Ireland and LS Control of Denmark. The acquired companies have combined annual sales of around SEK 3 billion.  Review of total costs as a result of weak...

Acceptable activity level but challenging profitability. AKVA group delivered revenue for Q4 of MNOK 800 (779), an increase of 3% compared to Q4 2022. EBITDA increased from MNOK 27 in Q4 2022 to MNOK 41 in Q4 2023. Adjusted for MNOK 10 in costs related to the rightsizing process EBITDA was MNOK 51 in Q4 2023. The rightsizing process, with estimated MNOK 45 in annual cost savings, was completed in Q4. Order intake of MNOK 718 (889) in Q4 and order backlog of BNOK 2,4 at the end of December 2023. The medium-term financial targets are revised and AKVA is aiming for revenue of minimum BNOK 3,6 and EBIT of 4-5% in 2024. The activity in 2023 was at the same level as last year. Overall, the order intake was sound with the award of RAS contract for Nordic Aqua Partners (MEUR 40) and the post smolt contract for Cermaq Norway (minimum MEUR 60)...

FULL YEAR RESULTS 2023 UMICORE 2023 FULL YEAR RESULTS Key highlightsRevenues* of € 3.9 billion (-7% vs. 2022) Adjusted EBITDA of € 972 million (-16% vs. 2022) and adjusted EBITDA margin of 25.0% (27.3% in 2022) Adjusted EBIT of € 674 million (-22% vs. 2022) ROCE of 13.5% (19.2% in 2022) Adjusted net profit (Group share) of € 447 million and adjusted EPS of € 1.86Cash flow from operations of € 1,217 million (€ 835 million in 2022); free operating cash flow  of € 332  million (€ 344 million in 2022) Capital expenditures of € 857 million (€ 470 million in 2022) Net debt at € 1,266 million, compared to € 1,104 million at the end of 2022. This corresponds to a net debt/ LTM adj. EBITDA ratio of 1.30 Proposed gross annual dividend for 2023 of € 0.80 of which € 0.55 to be paid in May 2024, with an interim dividend of € 0.25 already paid...

Oslo, Norway, 16th of February 2024 Vistin Pharma ASA (Vistin Pharma, OSE: VISTN) today announces the financial results for the fourth quarter of 2023. Vistin delivers another strong quarter with a 12% revenue growth compared to same quarter last year. Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 99 in Q4 2022. Sales volume in the quarter was up by 11%. Revenue for FY 2023 ended at MNOK 438 compared to MNOK 305 in 2022, a 44% increase. Fourth quarter EBITDA ended at MNOK 25 (Q4’22 MNOK 10). EBITDA are positively affected by increased sales volume, competitive electricity prices and a stronger EUR vs NOK, partly offset by a stronger USD vs NOK. In addition, positive economies of scale effects as the new manufacturing line ramps-up. 2023 FY EBITDA ended at MNOK 86 compared to MNOK 6 last year. The net profit ended at...